Table 6.

Variation in inflammatory markers during the study within each treatment group and between treatment groups.

Variable	n3 PUFA Group				Placebo Group
	Baseline t = 0	Final t = 4	p-Value a	Δ	Baseline t = 0	Final t = 4	p-Value a	Δ	p-Value b	q-Value c
IFNγ (pg/mL)	10.1 ± 12.9	12.2 ± 17.0	0.860	2.0 ± 24.1	2.4 ± 2.3	1.1 ± 1.0	0.348	−1.3 ± 2.8	0.764	0.910
IL-12 (pg/mL)	0.6 ± 0.3	0.6 ± 0.3	0.420	−0.3 ± 1.5	0.7 ± 0.4	0.6 ± 0.5	0.423	−0.1 ± 0.1	0.286	0.571
IL-13 (pg/mL)	1.0 ± 1.3	0.7 ± 0.5	0.573	−0.3 ± 1.5	0.4 ± 0.3	1.7 ± 3.6	0.402	1.2 ± 1.3	0.268	0.571
IL-8 (pg/mL)	4.1 ± 1.5	3.7 ± 1.8	0.341	−0.3 ± 2.4	6.2 ± 2.8	4.2 ± 2.8	0.014	−2.0 ± 3.3	0.097	0.425
IL-6 (pg/mL)	0.6 ± 0.4	1.1 ± 0.9	0.513	0.5 ± 0.2	0.7 ± 0.4	0.1 ± 0.3	0.443	−0.6 ± 0.3	0.182	0.535
MCP-1(pg/mL)	71.1 ± 65.6	53.1 ± 43.3	0.197	−17.9 ± 48.5	54.7 ± 36.7	40.6 ± 25.9	0.033	−14.0 ± 27.4	0.760	0.910
MIP1β (pg/mL)	21.4 ± 13.1	17.2 ± 12.3	0.193	−4.2 ± 12.9	22.2 ± 21.2	16.2 ± 13.1	0.169	−5.9 ± 18.5	0.759	0.910
Adiponectin (μg/mL)	3.0 ± 2.9	2.2 ± 1.7	0.284	−0.8 ± 3.1	3.5 ± 4.2	3.1 ± 3.5	0.671	−0.4 ± 4.5	0.765	0.910

IFNγ: Interferon gamma, IL-12: Interleukin-12, IL-13: Interleukin 13, IL-8: Interleukin 8, IL-6: Interleukin 6, MCP-1: Monocyte chemoattractant protein 1, MIP1 β: Macrophage inflammatory protein-1 β, Δ: final baseline data for all inflammatory markers. Data expressed in mean ± standard deviation (SD). t = 0 (time 0, baseline of the study), t = 4 (4 months, end of the study). ^a The intragroup comparisons (baseline vs. final) were performed with the paired Student’s t-test. ^b Delta comparisons between groups (intergroup) were analyzed with the independent Student’s t-test. ^c The q-values (intergroup) were adjusted with the Benjamini and Hochberg method to control for false-discovery rate.